Role of CD4 Count in Immunity Development After Hepatitis A and B Vaccination Among HIV-Infected Patients: Kentucky,2002-2007

Abstract

Purpose: To determine whether lower prevaccination CD4 counts decrease odds of immune development against hepatitis A virus/hepatitis B virus (HAV/HBV) among patients who receive the vaccine and examine the relationship between vaccine response and sex, race/ethnicity, health insurance status, tobacco use, substance abuse, or comorbidities. Methods: This study was performed among patients who received the standard dose for HAV and/or HBV vaccine. Results: Among 76 HIV-infected patients, immunity development to HAV or HBV increased as CD4 counts increased. In addition, males had greater vaccine response than females. Whites were observed to have higher rates of immunity than other races/ethnicities. Patients with private insurance had greater vaccine response than those with Medicaid, Medicare, or no insurance. Patients not experiencing hypertension and hyperlipidemia developed immunity more often than patients with these comorbidities. Substance abuse and tobacco use were also associated with lower vaccine response. Conclusions: Higher CD4 counts improved likelihood of patients developing an antibody response after vaccination.

Keywords

HIV vaccination hepatitis A hepatitis B

References

Tedaldi EM , Baker RK , Moorman AC , et al, and the HIV Outpatient Study (HOPS) Investigators. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis. 2004;38(10):1478-1484.

Centers for Disease Control and Prevention. Basic Information about HIV. http://www.cdc.gov/hiv/topics/basic/. Accessed November 9, 2008.

World Health Organization. Immunization against diseases of public health importance. http://www.who.int/mediacentre/factsheets/fs288/en/index.html. Accessed February 27, 2008.

Centers for Disease Control and Prevention. Ten great public health achievements-United States, 1900-1999 . MMWR Morb Mortal Wkly Rep. 1999;48(12):241-243.

Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 1997. MMWR Morb Mortal Wkly Rep. 1998;46(54):ii-vii, 3-87.

Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) . MMWR Morb Mortal Wkly Rep. 1999;48(RR-12):1-37.

GlaxoSmithKline. Twinrix prescribing information. http://us.gsk.com/products/assets/us_twinrix.pdf . Accessed February 14, 2008.

Laurence JC Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med. 2005; 118(suppl 10A):75S-83S.

Wallace MR , Brandt CJ , Earhart KC , et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis. 2004;39(8):1207-1213.

10.

Kemper CA , Haubrich R. , Frank I. , et al, for the California Collaborative Treatment Group. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis. 2003 ;187(8):1327-1331.

11.

Pasricha N. , Datta U. , Chawla Y. , et al. Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine. BMC Infect Dis . 2006;6:65.

12.

Fonseca MO , Pang LW , Cavalheiro NP , Barone AA , Lopes MH Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine . 2005;23(22):2902-2908.

13.

Overton ET , Nurutdinova D. , Sungkanuparph S. , Seyfried W. , Groger RK , Powderly WG Predictors of immunity after hepatitis A vaccination in HIV-infected persons . J Viral Hepat. 2007; 14(3):189-193.

14.

Weissman S. , Feucht C. , Moore BA Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat. 2006;13(2):81-86.

15.

Anastos K. , Gange SJ , Lau B. , et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr. 2000;24(3):218-226.

16.

Brown AE , Malone JD , Zhou SY , Lane JR , Hawkes CA Human immunodeficiency virus RNA levels in US adults: a comparison based upon race and ethnicity. J Infect Dis. 1997;176(3):794-797.

17.

Hogg RS , Strathdee SA , Craib KJ , O’Shaughnessy MV , Montaner JS , Schechter MT Lower socioeconomic status and shorter survival following HIV infection. Lancet. 1994; 344(8930):1100-1101.

18.

Curtis RJ , Patrick DL Race and survival time with AIDS: a synthesis of the literature. Am J Public Health. 1993;83(10): 1425-1428.

19.

Alder NE , Newman K. Socioeconomic disparities in health: pathways and policies. Health Aff (Millwood). 2002;21(2):60-76.

20.

Lincoln D. , Petoumenos K. , Dore GJ. for the Australian HIV Observational Database. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med. 2003;4(3):241-249.

21.

Lucas GM , Gebo KA , Chaisson RE , Moore RD Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002; 16(5):767-774.

22.

Wilson CM , Ellenberg JH , Sawyer MK , et al, for the Adolescent Medicine HIV/AIDS Research Network. Serologic response to Hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. J Adolesc Health. 2001; 29(3 suppl):123-129.

23.

Williams DR , Collins C. US socioeconomic and racial differences in health: patterns and explanations. Ann Rev Sociol. 1995;21: 349-386.

24.

Alder NE , Boyce WT , Chesney MA , Folkman S. , Syme SL Socioeconomic inequalities in health. No easy solution. J Am Med Assoc. 1993;269(24):3140-3145.